Skip to main content

Advertisement

Table 7 Expression of Cytokines (Th1, Th2 and Th17), IDO(a), PD-L1(b)and VEGF(c) in ALNs(d) in Women with LLABCs(e)Undergoing NAC(f)

From: Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC

(n = 16) Groups Low/Negative Expression (n) High Expression (n) Pearson Chi-Square Value P Value
IL-1 Non metastatic ALNs (n = 9) 3 6 0.042 0.838
Metastatic ALNs (n = 7) 2 5
IL-2 Non metastatic ALNs (n = 9) 1 8 8.905 0.003h
Metastatic ALNs (n = 7) 6 1
IL-4 Non metastatic ALNs (n = 9) 3 6 0.152 0.696
Metastatic ALNs (n = 7) 3 4
IL-10 Non metastatic ALNs (n = 9) 7 2 3.874 0.049h
Metastatic ALNs (n = 7) 2 5
IL-17 Non metastatic ALNs (n = 9) 1 8 2.116 0.146
Metastatic ALNs (n = 7) 3 4
IDO(g) Non metastatic ALNs (n = 9) 2 7 2.049 0.152
Metastatic ALNs (n = 7) 4 3
PD-L1 Non metastatic ALNs (n = 9) 7 2 0.085 0.771
Metastatic ALNs (n = 7) 5 2
IFN-γ Non metastatic ALNs (n = 9) 1 8 3.883 0.049h
Metastatic ALNs (n = 7) 4 3
TGF-β(g) Non metastatic ALNs (n = 9) 5 4 0.423 0.515
Metastatic ALNs (n = 7) 5 2
VEGF Non metastatic ALNs (n = 9) 6 3 0.762 0.383
Metastatic ALNs (n = 7) 6 1
  1. (a)IDO: Indoleamine 2,3-dioxygenase; (b)PDL-1: Programmed death ligand 1; (c)VEGF: Vascular endothelial growth factor; (d)ALNs: Axillary lymph nodes; (e)LLABCs: Large and locally advanced breast cancers; (f)NAC: Neoadjuvant chemotherapy; (g)IDO and TGF-β were scored as negative and positive; hStatistically significant